Federal Register / Vol. 86, No. 157 / Wednesday, August 18, 2021 / Notices 46257 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines for Children (VFC) program, 

along with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under provisions of the Affordable Care 

Act, section 2713 of the Public Health 

Service Act, immunization 

recommendations of the ACIP that have 

been approved by the Director of the 

Centers for Disease Control and 

Prevention and appear on CDC 

immunization schedules must be 

covered by applicable health plans. 

Matters To Be Considered: The agenda 

will include discussions on additional 

doses of COVID–19 vaccine, including 

booster doses. Agenda items are subject 

to change as priorities dictate. For more 

information on the meeting agenda visit 

https://www.cdc.gov/vaccines/acip/ 

meetings/meetings-info.html. 

Meeting Information: The meeting 

will be webcast live via the World Wide 

Web; for more information on ACIP 

please visit the ACIP website: http://

www.cdc.gov/vaccines/acip/index.html. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: Written 

comments must be received on or before 

August 24, 2021. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. Oral 

public comment will occur before any 

scheduled votes including all votes 

relevant to the ACIP’s Affordable Care 

Act and Vaccines for Children Program 

roles. Priority will be given to 

individuals who submit a request to 

make an oral public comment before the 

meeting according to the procedures 

below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the August 24, 2021, 

ACIP meeting must submit a request at 

http://www.cdc.gov/vaccines/acip/ 

meetings/ no later than 11:59 p.m., EDT, 

August 22, 2021, according to the 

instructions provided. 

If the number of persons requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

time, CDC will conduct a lottery to 

determine the speakers for the 

scheduled public comment session. 

CDC staff will notify individuals 

regarding their request to speak by email 

by 12:00 p.m., EDT, August 23, 2021. To 

accommodate the significant interest in 

participation in the oral public 

comment session of ACIP meetings, 

each speaker will be limited to 3 

minutes, and each speaker may only 

speak once per meeting. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–17808 Filed 8–16–21; 4:15 pm] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Single-Source 

Grant To Fund Task Force for Global 

Health, Inc. 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS) announces the 

award of approximately $47,000,000 in 

COVID–19 funding with an expected 

total funding of $100,000,000 over a 

five-year period to the Task Force for 

Global Health to expand the influenza 

and COVID–19 vaccine coverage in lowand middle-income countries. 

DATES: The period for this award will be 

September 30, 2021 through September 

29, 2026. 

FOR FURTHER INFORMATION CONTACT: 

Archana Kumar, National Center for 

Immunization and Respiratory Diseases, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

H24–8, Atlanta, GA 30329, Telephone: 

800–232–6348, E-Mail: eocevent445@

cdc.gov. 

SUPPLEMENTARY INFORMATION: The 

single-source award will introduce and/ 

or expand influenza vaccine programs, 

contribute to evidence base for 

influenza control and prevention, and 

leverage efforts to deploy pandemic 

vaccines to low- and middle-income 

countries. 

The Task Force for Global Health will 

be awarded as a single-source because of 

their specific experience collaborating 

with multiple partners in facilitating the 

use of influenza vaccines in low- to 

middle-income countries and in 

developing local and global evidence 

base for sustained use of lifesaving 

vaccines since 2014. The Task Force for 

Global Health is uniquely qualified to 

support countries to plan for, 

implement and evaluate COVID–19 

vaccination programs since they are 

currently working with the same risk 

groups using established tools and 

platforms under an existing cooperative 

agreement. The Task Force for Global 

Health leads the Partnership for 

Influenza Vaccine Introduction which 

includes ministries of health from 15 

countries, private industry, and the 

United Nations International Children’s 

Emergency Fund. This Partnership 

creates sustainable, seasonal influenza 

vaccination programs in the targeted 

countries, works with the World Health 

Organization to prepare for pandemic 

influenza, and supports countries’ 

efforts to control and prevent seasonal 

outbreaks. 

Summary of the Award 

Recipient: The Task Force For Global 

Health. 

Purpose of the Award: The purpose of 

award is to expand the use of influenza 

and COVID–19 vaccines in low- and 

middle-income countries (LMICs), 

support influenza vaccine introduction 

through a public-private partnership, 

establish an evidence base for global 

vaccine introduction decisions, and 

leverage this partnership to support 

readiness for and deployment of future 

pandemic vaccines. The recipient will 

be expected to assist partner countries 


jbell on DSKJLSW7X2PROD with NOTICES
46258 Federal Register / Vol. 86, No. 157 / Wednesday, August 18, 2021 / Notices 

to plan, implement, and evaluate 

vaccination programs for influenza and 

COVID–19. 

Amount of Award: $47,000,000 in 

Federal Fiscal Year (FFY) 2021 funds, 

and an estimated total of $100,000,000 

over the five-year period of 

performance, subject to availability of 

funds. 

Period of Performance: September 30, 

2021 through September 29, 2026. 

Authority: Section 307 of the Public 

Health Service Act, as amended (42 

U.S.C. 242l). 

Dated: August 12, 2021. 

Joseph I. Hungate III, 

Deputy Director, Office of Financial 

Resources, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2021–17678 Filed 8–17–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Notice of Meeting 

AGENCY: Office on Trafficking in 

Persons, Administration for Children 

and Families, Department of Health and 

Human Services. 

ACTION: Announcement of meeting and 

call for public comments on states’ 

efforts to improve the nation’s response 

to the sex trafficking of children and 

youth. 

SUMMARY: Notice is hereby given, 

pursuant to the provisions of the 

Federal Advisory Committee Act 

(FACA) and the Preventing Sex 

Trafficking and Strengthening Families 

Act, that a meeting of the National 

Advisory Committee on the Sex 

Trafficking of Children and Youth in the 

United States (the Committee) will be 

held on September 8 and 9, 2021. The 

purpose of the meeting is for the 

Committee to begin reviewing responses 

to the Committee’s State SelfAssessment Survey and develop a 

framework for the Committee’s final 

report. The members of the Committee 

request comments from the public to 

inform their ongoing work and final 

report. Please submit your comments to 

NAC@nhttac.org with the subject ‘‘NAC 

Comments’’ as soon as possible and 

before September 6, 2021. 

DATES: The meeting will be held on 

September 8 and 9, 2021. 

ADDRESSES: The meeting will be held 

virtually. Please register for this event 

online: https://www.acf.hhs.gov/otip/ 

partnerships/national-advisorycommittee. 

FOR FURTHER INFORMATION, CONTACT: 

Katherine Chon (Designated Federal 

Officer) at EndTrafficking@acf.hhs.gov 

or (202) 205–5778, or 330 C Street SW, 

Washington, DC 20201. Additional 

information is available at https://

www.acf.hhs.gov/otip/partnerships/thenational-advisory-committee. 

SUPPLEMENTARY INFORMATION: The 

formation and operation on behalf of the 

Committee are governed by the 

provisions of Public Law 92–463, as 

amended (5 U.S.C. App. 2), which sets 

forth standards for the formation and 

use of federal advisory committees. 

Purpose of the Committee: The 

purpose of the Committee is to advise 

the Secretary and the Attorney General 

on practical and general policies 

concerning improvements to the 

nation’s response to the sex trafficking 

of children and youth in the United 

States. HHS established the Committee 

pursuant to Section 121 of the 

Preventing Sex Trafficking and 

Strengthening Families Act of 2014 

(Pub. L. 113–183). 

Tentative Agenda: The agenda can be 

found at https://www.acf.hhs.gov/otip/ 

partnerships/the-national-advisorycommittee. To submit written 

statements, email NAC@nhttac.org, by 

September 6, 2021. Please include your 

name, organization, and phone number. 

More details on these options are below. 

Public Accessibility to the Meeting: 

Pursuant to 5 U.S.C. 552b and 41 CFR 

102–3.140 through 102–3.165, and 

subject to the availability of space, this 

meeting is open to the public virtually. 

Written Statements: Pursuant to 41 

CFR 102–3.105(j) and 102–3.140 and 

section 10(a)(3) of the Federal Advisory 

Committee Act, the public may submit 

written statements in response to the 

stated agenda of the meeting, or to the 

Committee’s mission, in general. 

Organizations with recommendations 

on strategies to engage states and 

stakeholders are encouraged to submit 

their comments or resources (hyperlinks 

preferred). Written comments or 

statements received after September 6, 

2021, may not be provided to the 

Committee until its next meeting. 

Verbal Statements: Pursuant to 41 

CFR 102–3.140d, the Committee is not 

obligated to allow a member of the 

public to speak or otherwise address the 

Committee during the meeting. 

Members of the public are invited to 

provide verbal statements during the 

Committee meeting only at the time and 

manner described in the agenda. The 

request to speak should include a brief 

statement of the subject matter to be 

addressed and should be relevant to the 

stated agenda of the meeting or the 

Committee’s mission in general. 

Minutes: The minutes of this meeting 

will be available for public review and 

copying within 90 days at: https://

www.acf.hhs.gov/otip/partnerships/thenational-advisory-committee. 

Linda Hitt, 

Director, Executive Secretariat. 

[FR Doc. 2021–17714 Filed 8–17–21; 8:45 am] 

BILLING CODE 4184–40–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Elizabeth Pitts, Ph.D., 240–669–5299; 

elizabeth.pitts@nih.gov. Licensing 

information may be obtained by 

communicating with the indicated 

licensing contact at the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852; tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Tumor Associated Calcium Signal 

Transducer 2 (TACSTD2)- 

Overexpressing Huh7.5 Cells That Are 

More Permissive to HCV Cell Entry and 

Replication Compared to the Model 

Huh7.5 Cell Line 

Description of Technology 

Worldwide, 130–150 million 

individuals are chronically infected 

with hepatitis C virus (HCV), a major 

cause of liver-associated morbidity and 

mortality worldwide. Despite recent 

advances in antiviral drugs that can cure 

some individuals, a rapid decline of the 


jbell on DSKJLSW7X2PROD with NOTICES